Moreover, patients with ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (also known as ErbB-2) triple-negative breast cancer, which is aggressive with high recurrence, metastatic and mortality rates,3 do not respond to hormonal therapies and have limited treatment options. Here, PGR is linked to triple-negative breast carcinoma.